Cancer Treatment Centers of America

Targeted therapy for kidney cancer

immunotherapy

Targeted therapy for kidney cancer

Targeted therapy is designed to identify receptors and proteins unique to specific cancer cells. Once attached to the targeted cancer cells, these drugs kill the cells or help other therapies, such as chemotherapy, work better. Among the drugs used in targeted therapy are so-called tyrosine kinase inhibitors, which target specific enzymes called protein kinases that help regulate cell growth. Inhibition of these pathways may interfere with pathways that encourage tumor growth. They also may inhibit new blood supplies from forming that deliver nutrients that help the cancer survive, and, in turn, cause the cancer cells to die.

Your oncologist may include one or more of the following kinase inhibitor drugs in your treatment plan: sunitinib (Sutent®), sorafenib (Nexavar®), pazopanib (Votrient®), temsirolimus (Torisel®), everolimus (Afinitor®, Zortress®), cabozantanib (Cabometyx®), lenvatinib (Lenvima®) and axitinib (Inlyta®).

Your doctor may also recommend bevacizumab (Avastin®), a monoclonal antibody and angiogenesis inhibitor designed to prevent cancer cells from developing blood vessels that feed tumors.

Many of these therapies are showing promise in combination with immunotherapy in the clinical trial setting. Ask your medical oncologist about available clinical trials for kidney cancer at Cancer Treatment Centers of America® (CTCA).